EluSys Therapeutics Adds Business Development Pro; Signals Focus on Exploring Licensing and Co-Marketing Opportunities
Apr 23, 2001, 01:00 ET from EluSys Therapeutics, Inc.
PINE BROOK, N.J. April 23 /PRNewswire Interactive News Release/ --
EluSys Therapeutics, Inc., a biopharmaceutical company focused on treatments
for blood-borne diseases, announced today that former Goldman Sachs vice
president Cynthia Beach, Ph.D., has joined the company as vice president of
business development.
"Cynthia Beach has an impressive background that combines more than a
decade of experience at pharmaceutical companies with a number of years
working in the financial industry analyzing the healthcare sector," said
Stephen Sudovar, president and CEO of EluSys. "Her knowledge and her
understanding of the leading companies in the pharmaceutical industry will
provide EluSys with the capability to execute the necessary strategic
collaborations to ensure our success. We are very happy to have Dr. Beach on
board."
Cynthia Beach, Ph.D.
Dr. Beach brings to EluSys nearly 25 years of experience in business
development at investment firms and in the healthcare industry. Previously,
she was vice president of global equity research at Goldman Sachs, where she
was a senior research analyst covering the U.S. pharmaceutical industry.
Before this she was vice president of equity research at Gerard Klauer
Mattison, following the healthcare industry.
From the mid-80s to the mid-90s, Dr. Beach worked in the pharmaceutical
industry, at Pfizer, Inc and Organon, Inc. As director of licensing and
development at Pfizer from 1991-1996, she helped establish a worldwide
strategic alliance with Eisai Co., Ltd. for the Alzheimer's drug Aricept and
negotiated Pfizer's alliance on neutrophil inhibitory factor for stroke with
Corvas International.
"The Heteropolymer System EluSys is developing is a very exciting
technology," commented Dr. Beach. "Its broad application has tremendous
potential for attracting pharmaceutical companies or even other biotech firms
as marketing partners or licensees who want to apply the technology to their
area of expertise."
The Heteropolymer System: "Biological Double-Sided Tape"
The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
technology designed to enable the body to use its own red blood cells to
efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
and autoantibodies. The HP System uses a proprietary bi-specific monoclonal
antibody (the Heteropolymer) which binds the target pathogen to red blood
cells, like a piece of biological double-sided tape. The red blood cells
carry the Heteropolymer-pathogen complex to the liver, where it is destroyed.
The HP System has been studied against ten different model or actual
pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
(toxin) and autoantibodies involved in the autoimmune diseases myasthenia
gravis and lupus.
Experiments show that the HP System can clear even substantial levels of a
variety of pathogens and autoantibodies from the bloodstream of nonhuman
primates within an hour. Other experiments have demonstrated that EluSys'
Heteropolymers may prevent pathogens from ever reaching appreciable
concentrations in the blood when injected before exposure.
About EluSys
EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
focused on developing treatments for a variety of blood-borne diseases.
EluSys' patented monoclonal antibody-based technology, the Heteropolymer
("HP") System, may offer a significant advance in the management and treatment
of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
effectiveness of the body's own natural defense mechanisms to remove such
pathogens from the blood and destroy them. EluSys recently signed a research
agreement with the U.S. Army Medical Research Institute of Infectious Diseases
(USAMRIID) to develop treatments for anthrax and other potential biowarfare
agents. Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
Additional information about EluSys, the HP technology and senior management
can be found at http://www.EluSys.com.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X76951038
SOURCE EluSys Therapeutics, Inc.
PINE BROOK, N.J. April 23 /PRNewswire Interactive News Release/ --
EluSys Therapeutics, Inc., a biopharmaceutical company focused on treatments
for blood-borne diseases, announced today that former Goldman Sachs vice
president Cynthia Beach, Ph.D., has joined the company as vice president of
business development.
"Cynthia Beach has an impressive background that combines more than a
decade of experience at pharmaceutical companies with a number of years
working in the financial industry analyzing the healthcare sector," said
Stephen Sudovar, president and CEO of EluSys. "Her knowledge and her
understanding of the leading companies in the pharmaceutical industry will
provide EluSys with the capability to execute the necessary strategic
collaborations to ensure our success. We are very happy to have Dr. Beach on
board."
Cynthia Beach, Ph.D.
Dr. Beach brings to EluSys nearly 25 years of experience in business
development at investment firms and in the healthcare industry. Previously,
she was vice president of global equity research at Goldman Sachs, where she
was a senior research analyst covering the U.S. pharmaceutical industry.
Before this she was vice president of equity research at Gerard Klauer
Mattison, following the healthcare industry.
From the mid-80s to the mid-90s, Dr. Beach worked in the pharmaceutical
industry, at Pfizer, Inc and Organon, Inc. As director of licensing and
development at Pfizer from 1991-1996, she helped establish a worldwide
strategic alliance with Eisai Co., Ltd. for the Alzheimer's drug Aricept and
negotiated Pfizer's alliance on neutrophil inhibitory factor for stroke with
Corvas International.
"The Heteropolymer System EluSys is developing is a very exciting
technology," commented Dr. Beach. "Its broad application has tremendous
potential for attracting pharmaceutical companies or even other biotech firms
as marketing partners or licensees who want to apply the technology to their
area of expertise."
The Heteropolymer System: "Biological Double-Sided Tape"
The EluSys Heteropolymer (HP) System is a monoclonal antibody-based
technology designed to enable the body to use its own red blood cells to
efficiently remove and destroy a wide variety of blood-borne pathogens, toxins
and autoantibodies. The HP System uses a proprietary bi-specific monoclonal
antibody (the Heteropolymer) which binds the target pathogen to red blood
cells, like a piece of biological double-sided tape. The red blood cells
carry the Heteropolymer-pathogen complex to the liver, where it is destroyed.
The HP System has been studied against ten different model or actual
pathogens, including dengue virus, Pseudomonas aeruginosa (bacteria), E. coli
(toxin) and autoantibodies involved in the autoimmune diseases myasthenia
gravis and lupus.
Experiments show that the HP System can clear even substantial levels of a
variety of pathogens and autoantibodies from the bloodstream of nonhuman
primates within an hour. Other experiments have demonstrated that EluSys'
Heteropolymers may prevent pathogens from ever reaching appreciable
concentrations in the blood when injected before exposure.
About EluSys
EluSys Therapeutics, Inc. is a privately held biopharmaceutical company
focused on developing treatments for a variety of blood-borne diseases.
EluSys' patented monoclonal antibody-based technology, the Heteropolymer
("HP") System, may offer a significant advance in the management and treatment
of blood-borne viruses, bacteria, toxins and autoantibodies by enhancing the
effectiveness of the body's own natural defense mechanisms to remove such
pathogens from the blood and destroy them. EluSys recently signed a research
agreement with the U.S. Army Medical Research Institute of Infectious Diseases
(USAMRIID) to develop treatments for anthrax and other potential biowarfare
agents. Founded in 1998, EluSys is headquartered in Pine Brook, NJ.
Additional information about EluSys, the HP technology and senior management
can be found at http://www.EluSys.com.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X76951038
SOURCE EluSys Therapeutics, Inc.
Share this article